Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Veritas In Silico Inc. ( (JP:130A) ) is now available.
Veritas In Silico Inc. has revised its financial forecast for FY2025, projecting a significant decrease in business revenue and operating profit due to delays in contract negotiations. The company is actively seeking alternatives and has achieved milestones in its drug discovery research, securing patents and entering joint research agreements to strengthen its market position.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the pharmaceutical industry, focusing on drug discovery and development. The company is engaged in platform-based and pipeline-based businesses, with advancements in drug discovery research and the creation of nucleic acid drugs for acute renal failure. They have secured patents in Japan, Europe, and the United States, and have entered into joint research agreements to enhance their pipeline creation.
Average Trading Volume: 259,148
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.51B
Learn more about 130A stock on TipRanks’ Stock Analysis page.